Cannabis induced dopamine release: an in-vivo SPECT study

Abi-Dargham, 1998, Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort, American Journal of Psychiatry, 155, 761

D'Souza, 2001, Cannabinoid antagonists. A treatment in search of an illness, Archives of General Psychiatry, 58, 330, 10.1001/archpsyc.58.4.330

D'Souza, 2000, Cannabinoids and psychosis: evidence from studies with i.v. THC in schizophrenic patients and controls (abstract), Schizophrenia Research, 41, 33, 10.1016/S0920-9964(00)90371-2

French, 1997, Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra, Neuroreport, 8, 649, 10.1097/00001756-199702100-00014

Linszen, 1994, Cannabis abuse and the course of recent onset schizophrenic disorders, Archives of General Psychiatry, 51, 273, 10.1001/archpsyc.1994.03950040017002

Negrete, 1999, Cannabis and schizophrenia

Tanda, 1997, Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism, Science, 276, 2048, 10.1126/science.276.5321.2048

Volkow, 1997, Relationship between subjective effects of cocaine and dopamine transporter occupancy, Nature, 386 (6627), 827, 10.1038/386827a0

Voruganti, 1997, Neuroleptic dysphoria may be the missing link between substance abuse and schizophrenia, Journal of Nervous and Mental Disease, 185, 463, 10.1097/00005053-199707000-00008

Voruganti, L., Slomka, P., Zabel, P., Costa, G., So, A., Mattar, A., Awad, A.G., 2001. Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology (in press).

Watson, 2000, Marijuana and medicine: assessing the science base. A summary of the 1999 Institute of Medicine report, Archives of General Psychiatry, 57, 547, 10.1001/archpsyc.57.6.547

Wise, 1996, Addictive drugs and brain stimulation reward, Annual Review of Neuroscience, 19, 319, 10.1146/annurev.ne.19.030196.001535